Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: a prospective cohort study
Initiation of efavirenz-based combination antiretroviral therapy (cART) is associated with Vitamin D deficiency, but the risk factors including efavirenz pharmacokinetics for cART-induced severe vitamin D deficiency (SVDD) and the impact of anti-tuberculosis (TB) cotreatment are not explored. We inv...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016 Aug 26
|
| In: |
Medicine
Year: 2016, Jahrgang: 95, Heft: 34, Pages: e4631 |
| ISSN: | 1536-5964 |
| DOI: | 10.1097/MD.0000000000004631 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/MD.0000000000004631 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/md-journal/Fulltext/2016/08230/Prevalence_and_risk_factors_for_efavirenz_based.38.aspx 
|
| Verfasserangaben: | Hanna Nylén, PhD, Abiy Habtewold, PhD, Eyasu Makonnen, PhD, Getnet Yimer, PhD, Leif Bertilsson, PhD, Jürgen Burhenne, PhD, Ulf Diczfalusy, PhD, Eleni Aklillu, PhD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1703413687 | ||
| 003 | DE-627 | ||
| 005 | 20230426114634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200703s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000004631 |2 doi | |
| 035 | |a (DE-627)1703413687 | ||
| 035 | |a (DE-599)KXP1703413687 | ||
| 035 | |a (OCoLC)1341344500 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Nylén, Hanna |e VerfasserIn |0 (DE-588)1213099730 |0 (DE-627)1703413148 |4 aut | |
| 245 | 1 | 0 | |a Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency |b a prospective cohort study |c Hanna Nylén, PhD, Abiy Habtewold, PhD, Eyasu Makonnen, PhD, Getnet Yimer, PhD, Leif Bertilsson, PhD, Jürgen Burhenne, PhD, Ulf Diczfalusy, PhD, Eleni Aklillu, PhD |
| 264 | 1 | |c 2016 Aug 26 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.07.2020 | ||
| 520 | |a Initiation of efavirenz-based combination antiretroviral therapy (cART) is associated with Vitamin D deficiency, but the risk factors including efavirenz pharmacokinetics for cART-induced severe vitamin D deficiency (SVDD) and the impact of anti-tuberculosis (TB) cotreatment are not explored. We investigated the prevalence of SVDD in HIV and TB-HIV coinfected patients and associated risk factors for treatment-induced SVDD. - Treatment-naïve Ethiopian HIV patients with (n = 102) or without (n = 89) TB co-infection were enrolled prospectively and received efavirenz-based cART. In TB-HIV coinfected patients, rifampicin-based anti-TB treatment was initiated 4 or 8 weeks before starting cART. Plasma 25-hydroxyvitamin D (25 [OH]D), cholesterol and 4-beta hydroxycholesterol concentrations were measured at baseline, 4th, 16th, and 48th week of cART. Plasma efavirenz concentrations were determined at 4th and 16th weeks of cART. - TB-HIV patients had significantly lower plasma 25 (OH)D3 levels than HIV-only patients at baseline. TB co-infection, low Karnofsky score, high viral load, and high CYP3A activity as measured by plasma 4β-hydroxycholesterol/cholesterol ratios were significant predictors of low 25 (OH)D3 levels at baseline. In HIV-only patients, initiation of efavirenz-based cART increased the prevalence of SVVD from 27% at baseline to 76%, 79%, and 43% at 4th, 16th, and 48th weeks of cART, respectively. The median 25 (OH)D3 levels declined from baseline by −40%, −50%, and −14% at 4th, 16th, and 48th weeks of cART, respectively. - In TB-HIV patients, previous anti-TB therapy had no influence on 25 (OH)D3 levels, but the initiation of efavirenz-based cART increased the prevalence of SVDD from 57% at baseline to 70% and 72% at the 4th and 16th weeks of cART, respectively. Median plasma 25 (OH)D3 declined from baseline by −17% and −21% at week 4 and 16 of cART, respectively. - Our results indicate low plasma cholesterol, high CYP3A activity, and high plasma efavirenz concentrations as significant predictors of early efavirenz-based cART-induced vitamin D deficiency. Low plasma 25 (OH)D3 level at baseline is associated with TB co-infection and HIV diseases progression. Initiation of efavirenz-based cART is associated with high incidence of SVDD, whereas rifampicin based anti-TB therapy co-treatment has no significant effect. Supplementary vitamin D during cART initiation may be beneficial for HIV patients regardless of TB coinfection. | ||
| 700 | 1 | |a Habtewold, Abiy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Makonnen, Eyasu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yimer, Getnet |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bertilsson, Leif |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 700 | 1 | |a Diczfalusy, Ulf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aklillu, Eleni |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d Baltimore, Md. : Lippincott Williams & Wilkins, 1922 |g 95(2016,34) Artikel-Nummer e4631, 10 Seiten |h Online-Ressource |w (DE-627)330613820 |w (DE-600)2049818-4 |w (DE-576)096290811 |x 1536-5964 |7 nnas |a Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency a prospective cohort study |
| 773 | 1 | 8 | |g volume:95 |g year:2016 |g number:34 |g pages:e4631 |a Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency a prospective cohort study |
| 856 | 4 | 0 | |u https://doi.org/10.1097/MD.0000000000004631 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/md-journal/Fulltext/2016/08230/Prevalence_and_risk_factors_for_efavirenz_based.38.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200703 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 999 | |a KXP-PPN1703413687 |e 3695065532 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1097/MD.0000000000004631"],"eki":["1703413687"]},"title":[{"title_sort":"Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency","title":"Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency","subtitle":"a prospective cohort study"}],"origin":[{"dateIssuedDisp":"2016 Aug 26","dateIssuedKey":"2016"}],"person":[{"given":"Hanna","family":"Nylén","role":"aut","display":"Nylén, Hanna","roleDisplay":"VerfasserIn"},{"family":"Habtewold","given":"Abiy","display":"Habtewold, Abiy","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Makonnen","given":"Eyasu","roleDisplay":"VerfasserIn","display":"Makonnen, Eyasu","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Yimer, Getnet","given":"Getnet","family":"Yimer"},{"family":"Bertilsson","given":"Leif","roleDisplay":"VerfasserIn","display":"Bertilsson, Leif","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Burhenne, Jürgen","given":"Jürgen","family":"Burhenne"},{"roleDisplay":"VerfasserIn","display":"Diczfalusy, Ulf","role":"aut","family":"Diczfalusy","given":"Ulf"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Aklillu, Eleni","given":"Eleni","family":"Aklillu"}],"name":{"displayForm":["Hanna Nylén, PhD, Abiy Habtewold, PhD, Eyasu Makonnen, PhD, Getnet Yimer, PhD, Leif Bertilsson, PhD, Jürgen Burhenne, PhD, Ulf Diczfalusy, PhD, Eleni Aklillu, PhD"]},"recId":"1703413687","language":["eng"],"relHost":[{"title":[{"title_sort":"Medicine","title":"Medicine"}],"note":["Gesehen am 26.11.20"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency a prospective cohort studyMedicine","recId":"330613820","language":["eng"],"pubHistory":["1.1922 -"],"part":{"volume":"95","text":"95(2016,34) Artikel-Nummer e4631, 10 Seiten","year":"2016","issue":"34","pages":"e4631"},"origin":[{"dateIssuedDisp":"1922-","dateIssuedKey":"1922","publisher":"Lippincott Williams & Wilkins","publisherPlace":"Baltimore, Md."}],"id":{"issn":["1536-5964"],"zdb":["2049818-4"],"eki":["330613820"]},"physDesc":[{"extent":"Online-Ressource"}]}],"note":["Gesehen am 03.07.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a NYLENHANNAPREVALENCE2016 | ||